Endologix Completes Enrollment in PEVAR Randomized Trial
Endologix, Inc. (Nasdaq: ELGX) announced today the completion of patient enrollment in the Company's prospective, multicenter, randomized clinical trial of a bilateral percutaneous approach to endovascular abdominal aortic aneurysm repair.
Endologix is the first Company to receive United States Food and Drug Administration approval of an Investigational Device Exemption to evaluate percutaneous EVAR (PEVAR) for the treatment of abdominal aortic aneurysms (AAAs). The Company expects to submit a supplement to its premarket approval application with the primary endpoint results to request FDA approval for this broadened PEVAR indication during the second quarter of 2012.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.